Literature DB >> 34767936

Longitudinal Preclinical Imaging Characterizes Extracellular Drug Accumulation After Radiation Therapy in the Healthy and Leukemic Bone Marrow Vascular Microenvironment.

Jamison Brooks1, Darren Zuro1, Joo Y Song2, Srideshikan Sargur Madabushi3, James F Sanchez4, Chandan Guha5, Marcin Kortylewski6, Bihong T Chen7, Kalpna Gupta8, Guy Storme9, Jerry Froelich10, Susanta K Hui11.   

Abstract

PURPOSE: Recent initial findings suggest that radiation therapy improves blood perfusion and cellular chemotherapy uptake in mice with leukemia. However, the ability of radiation therapy to influence drug accumulation in the extracellular bone marrow tissue is unknown, due in part to a lack of methodology. This study developed longitudinal quantitative multiphoton microscopy (L-QMPM) to characterize the bone marrow vasculature (BMV) and drug accumulation in the extracellular bone marrow tissue before and after radiation therapy in mice bearing leukemia. METHODS AND MATERIALS: We developed a longitudinal window implant for L-QMPM imaging of the calvarium BMV before, 2 days after, and 5 days after total body irradiation (TBI). Live time-lapsed images of a fluorescent drug surrogate were used to obtain measurements, including tissue wash-in slope (WIStissue) to measure extracellular drug accumulation. We performed L-QMPM imaging on healthy C57BL/6 (WT) mice, as well as mice bearing acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
RESULTS: Implants had no effects on calvarium dose, and parameters for wild-type untreated mice were stable during imaging. We observed decreased vessel diameter, vessel blood flow, and WIStissue with the onset of AML and ALL. Two to 10 Gy TBI increased WIStissue and vessel diameter 2 days after radiation therapy in all 3 groups of mice and increased single-vessel blood flow in mice bearing ALL and AML. Increased WIStissue was observed 5 days after 10 Gy TBI or 4 Gy split-dose TBI (2 treatments of 2 Gy spaced 3 days apart).
CONCLUSIONS: L-QMPM provides stable functional assessments of the BMV. Nonmyeloablative and myeloablative TBI increases extracellular drug accumulation in the leukemic bone marrow 2 to 5 days posttreatment, likely through improved blood perfusion and drug exchange from the BMV to the extravascular tissue. Our data show that neo-adjuvant TBI at doses from 2 Gy to 10 Gy conditions the BMV to improve drug transport to the bone marrow.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34767936      PMCID: PMC9038217          DOI: 10.1016/j.ijrobp.2021.10.146

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   8.013


  37 in total

Review 1.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

2.  FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.

Authors:  Preetesh Jain; Hun Ju Lee; Wei Qiao; William Wierda; Ohad Benjamini; Jan Burger; Alessandra Ferrajoli; Zeev Estrov; Hagop Kantarjian; Michael Keating; Susan O'Brien
Journal:  Cancer       Date:  2014-07-15       Impact factor: 6.860

3.  MRI Study on the Changes of Bone Marrow Microvascular Permeability and Fat Content after Total-Body X-Ray Irradiation.

Authors:  Kejun Wang; Yunfei Zha; Hao Lei; Xiao Xu
Journal:  Radiat Res       Date:  2017-12-18       Impact factor: 2.841

4.  Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging.

Authors:  T M Moehler; H Hawighorst; K Neben; G Egerer; J Hillengass; R Max; A Benner; A D Ho; G van Kaick; H Goldschmidt
Journal:  Int J Cancer       Date:  2001-09       Impact factor: 7.396

5.  Dynamic contrast enhanced optical imaging of capillary leakage.

Authors:  N Faye; L Fournier; D Balvay; F Taillieu; C Cuenod; N Siauve; O Clement
Journal:  Technol Cancer Res Treat       Date:  2011-02

Review 6.  Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.

Authors:  Phyllis Wachsberger; Randy Burd; Adam P Dicker
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

Review 7.  Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.

Authors:  Boglarka Gyurkocza; Brenda M Sandmaier
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

Review 8.  An update of current treatments for adult acute myeloid leukemia.

Authors:  Hervé Dombret; Claude Gardin
Journal:  Blood       Date:  2015-12-10       Impact factor: 22.113

9.  Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect.

Authors:  Esther A Kleibeuker; Emmanouil Fokas; Philip D Allen; Veerle Kersemans; Arjan W Griffioen; John Beech; Jaehong H Im; Sean C Smart; Kitty C Castricum; Jaap van den Berg; Iris A Schulkens; Sally A Hill; Adrian L Harris; Ben J Slotman; Henk M Verheul; Ruth J Muschel; Victor L Thijssen
Journal:  Oncotarget       Date:  2016-11-22

Review 10.  Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.

Authors:  Yolla Haibe; Malek Kreidieh; Hiba El Hajj; Ibrahim Khalifeh; Deborah Mukherji; Sally Temraz; Ali Shamseddine
Journal:  Front Oncol       Date:  2020-02-27       Impact factor: 6.244

View more
  1 in total

1.  Development and characterization of a preclinical total marrow irradiation conditioning-based bone marrow transplant model for sickle cell disease.

Authors:  Srideshikan Sargur Madabushi; Raghda Fouda; Hemendra Ghimire; Amr M H Abdelhamid; Ji Eun Lim; Paresh Vishwasrao; Stacy Kiven; Jamison Brooks; Darren Zuro; Joseph Rosenthal; Chandan Guha; Kalpna Gupta; Susanta K Hui
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.